Semaglutide, tirzepatide and retatrutide are often discussed as if they were three versions of the same thing. In a research setting they are not. They differ in how many receptors they engage, how they are built, and therefore in what kinds of questions they can answer. This guide lays out the structural and pharmacological differences so a lab can pick the right tool for the model it is running.
The one-line version
- Semaglutide is a single-receptor agonist. It acts on the GLP-1 receptor only.
- Tirzepatide is a dual agonist. It acts on the GLP-1 receptor and the GIP receptor.
- Retatrutide is a triple agonist. It acts on the GLP-1, GIP and glucagon receptors.
Everything else in this article follows from that count.
Structure and origin
All three are synthetic peptides derived from the incretin hormone family. Semaglutide is a modified analog of human GLP-1 with two amino-acid substitutions and a C18 fatty diacid chain attached through a linker. That chain binds albumin in circulation, which is what stretches its half-life to roughly a week in the published pharmacokinetic literature.
Tirzepatide is a 39-amino-acid peptide built on a GIP backbone and engineered so that it also activates the GLP-1 receptor. It carries a C20 fatty diacid moiety for the same albumin-binding reason.
Retatrutide is also a 39-amino-acid peptide with a fatty diacid chain, but its sequence was tuned so that it activates a third receptor, the glucagon receptor, in addition to GLP-1 and GIP. Published pharmacology describes its potency as unbalanced by design, with relatively stronger GIP activity and weaker glucagon activity, so that the three signals combine in a specific ratio.
What each receptor contributes in a model
GLP-1 receptor signaling is the most studied of the three. In preclinical models it is associated with glucose-dependent insulin release, slowed gastric emptying and reduced food intake through central pathways.
GIP receptor signaling was long considered the weaker incretin. Newer work on dual agonists suggests GIP activity contributes additively to energy-balance effects and may blunt some of the gastrointestinal side effects seen with GLP-1 activity alone.
Glucagon receptor signaling is the counterintuitive one. Glucagon raises hepatic glucose output, which sounds like the wrong direction. In the triple-agonist literature its contribution is framed around increased energy expenditure and hepatic fat handling, with the GLP-1 and GIP components offsetting the glucose effect.
Choosing between them for a study
| Question you are asking | Usual pick | Why |
|---|---|---|
| Pure GLP-1 receptor pharmacology, or a comparator for a new GLP-1 compound | Semaglutide | Single target, deepest literature, well-characterized dose-response curves |
| Additive effect of GIP on top of GLP-1 | Tirzepatide vs semaglutide | The pair isolates the GIP contribution |
| Energy expenditure and hepatic outcomes with glucagon activity in the mix | Retatrutide | Only one of the three with glucagon receptor activity |
| Head-to-head receptor-count series | All three | One, two and three receptors from the same peptide family |
Practical handling in the lab
All three ship as lyophilized powder and are reconstituted before use. Because each carries a fatty-acid side chain, they are more hydrophobic than native GLP-1 and tend to reconstitute cleanly in bacteriostatic water with gentle swirling rather than shaking. Our guide to reconstitution math covers volumes and concentrations, and storage and stability covers what happens after the vial is opened.
Each of these compounds is available in several vial sizes. The size guide explains how labs pick between them.
What the Certificate of Analysis tells you
For any of the three, the two numbers that matter on a COA are HPLC purity and mass-spectrometry identity. Identity matters more than usual here because the three peptides have similar lengths and similar side chains. A mass spectrum is the only routine test that confirms which of the three is actually in the vial. Read our guide to reading a COA before comparing vendors.
A note on the cagrilintide combination
Retatrutide is also offered here as a retatrutide and cagrilintide pairing. Cagrilintide is not an incretin at all. It is a long-acting amylin analog, and amylin receptor signaling is a separate axis from the three receptors discussed above. Labs that add it are usually modeling a fourth signal on top of the triple agonist rather than comparing within the incretin family. The two compounds are supplied as separate components and should be logged separately in reconstitution records.
Common mistakes when comparing the three
- Comparing by milligram. The three have different potencies at each receptor. Equal mass is not equal activity, and equal activity at one receptor is not equal activity at another.
- Treating GIP as a minor add-on. In the dual- and triple-agonist literature the GIP component carries real weight in energy-balance outcomes, and its removal changes results.
- Ignoring the fatty-acid chain in solubility work. All three are albumin binders. In serum-free cell media that binding partner is absent, and the compounds behave differently than they do in plasma.
- Assuming identity from the label. Three similar-length lipidated peptides look alike on HPLC. Mass spectrometry is the only routine identity check that separates them.
The amylin side of that pairing, and how the two lipidated components are logged and handled, gets its own treatment in retatrutide and cagrilintide explained.
For a single-compound treatment of the triple agonist, its engineered receptor ratio and the vial sizes we carry, see what is retatrutide.
Frequently asked questions
Are these three interchangeable in a protocol?
No. They engage different receptor sets and have different potencies at each receptor. A protocol built around one cannot be assumed to transfer to another.
Why does retatrutide have glucagon activity if glucagon raises glucose?
The published design rationale is that glucagon receptor activity contributes to energy expenditure and liver fat handling, while the GLP-1 and GIP components counterbalance its effect on glucose. The ratio between the three activities is engineered, not accidental.
Which has the longest half-life?
All three are once-weekly class compounds in the clinical literature, with half-lives in the range of five to seven days. Exact values vary by study and model.
References
- Knudsen LB, Lau J. 2019. The discovery and development of liraglutide and semaglutide. Frontiers in Endocrinology.
- Coskun T, et al. 2018. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Molecular Metabolism.
- Coskun T, et al. 2022. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metabolism.
- Müller TD, et al. 2019. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism.
Research use only. Everything in this article describes laboratory and preclinical research. Homegrown Peptides products are not for human or animal use, are not drugs, and are not intended to diagnose, treat, cure or prevent any disease. Nothing here is medical advice or a protocol.
